Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)

Transcription

1 Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013

2 Systemic therapy for NSCLC in 2013 (What you should know) Evolution of chemotherapy and targeted agents in advanced lung cancer Adjuvant chemotherapy in resectable stage I III Chemotherapy in unresectable stage III

3 Cancer Incidence in Thailand 2008 Population (Millions) Total 65 Males 32 Females 33 Source: US Census Bureau, International Data Base Females Males Liver Liver Breast Cancer Site Colon and Rectum Urinary bladder Uterine Cervix Colon and Rectum Incidence, Prevalence, Mortality, and Mortality-to-Incidence Ratios for Common Cancers in Males and Females Long and Bronchus Non-Hodgkin Lymphoma Lung and Bronchus Age-Standardized Rate per 100, Incidence Number of New Cases of Cancer 10,195 6,429 2,744 1,195 1,336 6,243 4,995 5,282 3,026 2,108 Rate per 100,000 (not agestandardized) Year Prevalence Number of Persons Living with Cancer 4,984 4,875 6,488 3,283 2,681 19,846 2,390 19,096 2,412 5,147 Mortality Age-Standardized Rate per 100, Mortality-to- Incidence Ratio MR:IR Age-standardized to the World Standard Population. Source: GLOBOCAN 2002, IARC. US Census Bureau International Data Base country population for 2002 used as weights for prevalence rates Pfizer Inc. All rights reserved.

4

5 Advanced NSCLC: what are our treatment goals for patients? Longer life increased overall survival Better life symptom improvement prolonged time to progression improved disease control rate reduced toxicity improved quality of life (QoL)

6 Significant milestones in lung cancer therapy Survival (%) Supportive care + CT Supportive care Time from randomisation (months) 1990s Meta-analyses confirm survival benefit with chemotherapy in advanced NSCLC NSCLC Collaborative Group. BMJ 1995;311: Results shown for cisplatin-based regimens only (11 trials)

7 Significant milestones in lung cancer therapy 12 Median survival (months) BSC 2 4 months Cisplatinbased regimens: 6 8 months Platinumbased doublets (3G): 8 10 months Bevacizumab/ Cetuximab + platinum-based doublet: >12 months s 1980s

8 First-Line Therapy Platinum-Based Regimens in stage IV NSCLC Summary of conventional doublets Column A: Cisplatin Carboplatin Column B: Paclitaxel Docetaxel Gemcitabine Pemetrexed* Irinotecan Vinorelbine Etoposide Column C: Bevacizumab Cetuximab Doublets Regimen: Choose I from each column * Non-squamous histology

9

10 Pac Paclitxel; G gemcitabine; Vin vinorelbine; Doc docetaxel

11 Treatment Options for Advanced NSCLC (The Evolution) 1 st line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib EGFR TKI : inhibitors of Tyrosine kinase domain epidermal growth factor receptor Gefetinib, Erlotinib

12 Treatment Options for Advanced NSCLC (The recent Paradigm) 1 st line Maintenance Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed +Bevacizumab +Cetuximab 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib EGFR TKI : inhibitors of Tyrosine kinase domain epidermal growth factor receptor Gefetinib, Erlotinib Cetuximab monoclonal antibody to extracellular domain of EFGR Bevacizumab monoclonal antibody to vascular endothelial growth factor (VEGF)

13 Treatment Options for Advanced NSCLC (The recent Paradigm) 1 st line Maintenance 2 nd line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine +Bevacizumab Platinum + docetaxel +Cetuximab Platinum + vinorelbine Platinum + pemetrexed Not reimburse in Thailand!! Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib Required authorization

14 Treatment Options for Advanced NSCLC (The Real world) 1 st line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib Required authorization

15 Treatment Options for Advanced NSCLC (The Very Real world) 1 st line Standard platinum based regimens Platinum + paclitaxel 2 nd line Docetaxel Required authorization

16

17 Important considerations for optimising outcomes when selecting therapy for NSCLC Molecular markers (EGFR, ALK) IHC Histology Squamous (1/3 patients) FISH Squamous-cell carcinoma PCR Non-squamous (2/3 patients) EGFR epidermal growth factor receptor ALK anaplastic lymphoma kinase Adenocarcinoma Large-cell carcinoma

18 Cetuximab (Erbitux) The EGFR/HER Family Trastuzumab (Herceptin) TGFα EGF Ligand binding domain Epi β-cel (-) HB-EGF Amp (-) HRG (NRG1) Epi HB-GF NRG1 NRG2 NRG3 NRG4 Transmembrane Tyrosine kinase domain (-) erb-b1 EGFR HER1 neu Erb-b2 HER2 Erb-b3 HER3 Erb-b4 HER4 Gefitinib (Iressa) Erlotinib (Tarceva) Lapatinib (Tykerb)

19 Common clinical characteristics of NSCLC patients with EGFR mutations Ethnicity: Asian Wildtype Mut+ Wild type Mut+ Smoking history: never smoker Gender: female Mut+ Wildtype Wildtype Mut+ Histology: adenocarcinoma 60% of all EGFR mutation-positive Retrospective review of 2,880 cases Mitsudomi, et al. Int J Clin Oncol 2006 patients Mok, et al. NEJM 2009

20 Any Factor to Consider When Treatment NSCLC Histology is increasingly important when making treatment decisions for advanced NSCLC Pemetrexed is more effective in non-squamous histology Bevacizumab is more toxic in squamous histology Molecular marker now guides treatment decisions in specific groups of patients patients with EGFR mutation-positive disease gain more benefit from EGFR TKIs (Gefetinib, erlotinib) than chemotherapy in both first and second line patients with rearrangements of the anaplastic lymphoma kinase (ALK) gene gain more benefit from ALK TKI (crizotinib) than chemotherapy in second line therapy

21 EGFR TKI as first-line treatment for patients with EGFR mutation positive advanced NSCLC EGFR TKI Gefetinib, Erlotinib, Afatinib [TITLE]

22 Why EGFR TKI in first-line treatment? A EGFR Act MUT+ NSCLC First-line EGFR TKI PD PD Second-line chemotherapy (3rd line) Death B First-line chemotherapy PD Second-line EGFR TKI PD (3 rd line) Death C D First-line EGFR TKI PD First-line Rapid chemotherapy worsening PD Rapid worsening Death Death Patients who receive only one line of therapy Theoretical survival Gridelli, et al. Lung Cancer 2011

23 Important considerations for optimising outcomes when selecting therapy for NSCLC Molecular markers (EGFR, ALK) Histology Squamous (1/3 patients) Issue of testing in Thailand Availability of test Availbility of drugs Turn around time Reimbursement Squamous-cell carcinoma Non-squamous (2/3 patients) PCR Adenocarcinoma Large-cell carcinoma

24 EGFR TKI as first-line treatment for patients with EGFR mutation positive advanced NSCLC Study Chemo. PFS (Hazard Ratio) OS (hazard Ratio) IPASS Carboplatin/Paclitaxel X 6 cycles VS Gefetinib 0.48 ( ), p < NS WJTOG3405 Cisplatin/Docetaxel X 3-6 cycles VS Gefetinib ( ), p < NS NEJSG 002 Carboplatin/Paclitaxel > 3 cycles Vs Gefetinib 0.30 ( ), p < NS OPTIMAL Carboplatin/Gemcitabine X 4 cycles VS Erlotinib HR=0.16 ( ) Log-rank p< NS EURTAC Chemotherapy HR 0 37 ( ) NR VS Erlotinib ; p< Mok TS, et al. N Engl J Med 2009, Mitsudomi T, et al. Lancet Oncol 2010, Maemondo M, et al. N Engl J Med 2010., Zhou, et al. Lancet Oncol 2011; Rosell, et al. Lancet Oncol 2012

25 Treatment Options for Advanced NSCLC carbo + paclitaxel (+ BV or Ctux) Standard platinum cisplatin + gemcitabine (+ BV or Ctux) based carboplatin + docetaxel (+ Ctux) regimens Maintenance cisplatin + vinorelbine (+ Ctux) therapy Not reimburse in Thailand!! 1 st line 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib Not reimburse In Thailand!! 3+ line Erlotinib/ Gefitinib Required authorization

26

27 Updates in Community Oncology 2011: A Focus on Non-Small-Cell Lung Cancer Chemotherapy Today and the Need for Targeted Therapies The choice of treatment depends upon the histologic subtype, molecular abnormalities, general medical condition. Doublet chemotherapy for 4-6 cycles is standard (good PS) Targeted drugs can add to doublet chemotherapy Bevacizumab and cetuximab with survival benefit Targeted agents where target is known can replace firstline chemotherapy (EGFR-TKI in EGFR mutants) Most patients eventually progress and require additional therapy. Maintenance therapy improves survival Second-line therapy improves survival

28 Updates in Community Oncology 2011: A Focus on Non-Small-Cell Lung Cancer Lung Cancer Molecular Consortium Analysis in Lung Adenocarcinomas No Mutation Detected KRAS 22% AKT1 NRAS MEK1 MET AMP HER2 PIK3CA 2% BRAF 2% Double Mutants 3% EML4-AKL 7% EGFR 17% Mutations found in 54% (280/516) of tumors completely tested (95% CI: 50% to 59%) Kris MG, et al. ASCO CRA7506. Johnson BE, et al. IASLC WCLC Abstract O16.01

29 NSCLC Meta-analysis of Cisplatin Containing Regimens in Adjuvant Lung Cancer 8 cisplatin-based trials examined (n = 1394) Patients randomized to surgery alone or surgery + adjuvant chemotherapy 13% reduction in risk of death with surgery + adjuvant chemotherapy vs surgery alone (P =.08) Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:

30 Major Changes in New Staging Classification T and M Descriptors N0 N1 N2 N3 6th Edition TNM 7th Edition TNM Stage Stage Stage Stage T1 ( 3 cm) T1a ( 2 cm) IA IIA IIIA IIIB T1b (> 2-3 cm) IA IIA IIIA IIIB T2a (> 3-5 cm) IB IIA (IIB) IIIA IIIB T2 (> 3 cm) T2b (> 5-7 cm) IIA (IB) IIB IIIA IIIB T3 (> 7 cm) IIB (IB) IIIA (IIB) IIIA IIIB T3 invasion T3 IIB IIIA IIIA IIIB T4 (same lobe nodules) T3 IIB (IIIB) IIIA (IIIB) IIIA (IIIB) IIIB T4 (extension) T4 IIIA (IIIB) IIIA (IIIB) IIIB IIIB M1 (ipsilateral lung) T4 IIIA (IV) IIIA (IV) IIIB (IV) IIIB (IV) T4 (pleural effusion) M1a IV (IIIB) IV (IIIB) IV (IIIB) IV (IIIB) M1 (contralateral lung) M1a IV IV IV IV M1 (distant) M1b IV IV IV IV Goldstraw P, et al. J Thorac Oncol. 2007;2: IASLC staging handbook in thoracic oncology. Orange Park, Fl: Editorial Rx Press; 2009.

31 Positive Adjuvant NSCLC Studies Since 1995 Meta-analysis Study Rx n 5-Yr OS, % HR IALT [1] IB-IIIA CALGB [2] IB JBR.10 [3] IB-II ANITA [4,5] IB, II, IIIA Surgery Cis + VP16/vinca Surgery Carbo/paclitaxel Surgery Cis/vinorelbine Surgery Cis/vinorelbine Arriagada R, et al. N Engl J Med. 2004;350: Strauss GM, et al. J Clin Oncol. 2008;26: Winton T, et al. N Engl J Med. 2005;352: Douillard JY, et al. Lancet Oncol. 2006;7: Douillard JY, et al. ASCO Abstract 7013.

32 LACE Meta-analysis of Adjuvant Chemotherapy : Adjuvant Chemotherapy: Is It for Everyone? Category No. Deaths/ No. Patients HR for OS (Chemo vs Control) HR (95% CI) Stage IA 104/ ( ) Stage IB 515/ ( ) Stage II 893/1616 Test for trend: P = ( ) Stage III 878/ ( ) Chemotherapy Better Control Better Chemotherapy may be detrimental for stage IA, but stage IA patients were generally not given the potentially best combination cisplatin + vinorelbine (13% of stage IA patients vs 43% for other stages) Pignon JP, et al. J Clin Oncol. 2008;26:

33 Adjuvant Chemotherapy : What Lessons Have We Learned For whom : Stage II-IIIA IB? Not for IA Which Agents Platinum agents important : cisplatin Not enough data available on carboplatin Vinorelbine effective Not enough data on other drugs with appropriate dose of cisplatin

34 Phase III NATCH Study: Post-op chemo vs Pre-op chemo vs Surgery Alone Untreated patients with resectable stage IA (T > 2 cm), IB, II and T3N1 NSCLC (N = 624) Stratified by tumor size (< 3 vs 3-5 vs > 5 cm) and age ( 60 vs > 60 yrs) Paclitaxel 200 mg/m 2 + Carboplatin AUC 6 every 3 wks for 3 cycles (n = 201) Surgery (n = 212) Surgery (n = 181) Primary endpoint: 5-yr DFS Secondary endpoints: toxicity, OS, biomarker analysis Surgery (n = 211) Paclitaxel 200 mg/m 2 + Carboplatin AUC 6 every 3 wks for 3 cycles (n = 139) Felip E, et al. J Clin Oncol. 2010;28:

35 Adjuvant vs Preop Chemotherapy vs Surgery Alone: NATCH Phase III Results Treatment Arm Surgery alone Chemo surgery Surgery chemo Outcome 5-Yr DFS, % 5-Yr OS, % Median OS,Mos More patients in preoperative chemotherapy arm received treatment Similar resectability rates, surgical procedures, postoperative mortality across arms Felip E, et al. J Clin Oncol. 2010;28: Felip E, et al. ASCO Abstract 7500.

36 NATCH: Clinical Stages of Patients on Enrollment Clinical Stage, % Preop Chemotherapy (n = 199) Surgery Alone (n = 210) Adjuvant Chemotherapy (n = 210) T1N T2N T1N T2N T3N T3N T4N0* *Patient not eligible. Felip E, et al. J Clin Oncol. 2010;28:

37 Phase III Targeted Therapy Adjuvant Trials Trial Stage Therapy Target N Primary Endpoint JBR.19 [1] IB-IIIA Gefitinib x 2 yrs RADIANT [2] I-IIIA Erlotinib x 2 yrs MAGRIT [3] IB-IIIA Vaccine x 27 mos E1505 [4] IB ( 4 cm)- IIIA Chemo ± bevacizumab EGFR- IHC+ 503 OS 945 DFS MAGE-A DFS 1500 OS 1. Goss GD, et al. ASCO Abstract LBA ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT

38 Management of stage III non-small cell lung cancer Resected stage IIIA disease Adjuvant chemotherapy with a cisplatin-based doublet Post-op RT : N2, margin+/uncertain,? LN sampling Unresected stage III disease : +N2 or N3 documented prior to definitive treatment (Induction chemo ) Concurrent chemoradiotherapy with a platinum-based doublet ( consolidation chemo) Sequential chemotherapy followed by definitive RT RT alone? Surgery after induction Chemo or Chemo-RT.